At a glance
- Originator Vertex Pharmaceuticals
- Class Antipsoriatics
- Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis; Transplant rejection; Viral infections
Most Recent Events
- 13 Nov 2003 Interim data from a media release have been added to the adverse events and Skin Disorders therapeutic trials sections
- 23 May 2003 Vertex Pharmaceuticals has completed enrolment in a phase IIa trial for Psoriasis in Iceland
- 24 Dec 2002 Phase-II clinical trials in Psoriasis in Iceland (unspecified route)